SCHEMBL6152523

SCHEMBL6152523

COc1ccc(-c2c[nH]c(-c3ccc(OC)cc3)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.50
MAPT P10636 3/20 0.50
THRB P10828 1/20 0.50
PKM P14618 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
NPC1 O15118 5/20 0.49
RAB9A P51151 5/20 0.49
MAPK1 P28482 2/20 0.49
DYRK1A Q13627 2/20 0.47
SCN4A P35499 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
CASP3 P42574 2/20 0.47
SENP8 Q96LD8 2/20 0.47
SENP7 Q9BQF6 2/20 0.47
SENP6 Q9GZR1 2/20 0.47
TP53 P04637 1/20 0.47
ESR2 Q92731 1/20 0.47
ALDH1A1 P00352 3/20 0.45
MAP2K1 Q02750 1/20 0.44
ABL1 P00519 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28326433 0.93 ACHE (0.52) KDM4EMAPTTHRBPKMTDP1
SCHEMBL19664327 0.93 SCN2A (0.50) KDM4EMAPTTHRBPKMTDP1
SCHEMBL20392617 0.93 SCN2A (0.50) KDM4EMAPTTHRBPKMTDP1
SCHEMBL2786777 0.88 MAPT (0.43) KDM4EMAPTTHRBPKMTDP1
SCHEMBL28326393 0.87 RAB9A (0.42) KDM4EMAPTTHRBPKMTDP1
SCHEMBL14013397 0.82 KDM4E (0.49) KDM4EMAPTTHRBPKMTDP1
SCHEMBL25374033 0.82 HSP90AA1 (0.42) KDM4EMAPTTHRBPKMTDP1
SCHEMBL186791 0.79 RAB9A (0.44) KDM4EMAPTTHRBPKMTDP1
SCHEMBL7212912 0.78 DYRK1A (0.47) KDM4EMAPTTDP1NPC1RAB9A
SCHEMBL28327646 0.78 KDM4E (0.45) KDM4EMAPTTHRBPKMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115141220-B Aza-BODIPY compound and application thereof in nanoparticle in-vivo tracking 复旦大学 2025-03-11 CN claimed
CN-115141220-A Aza-BODIPY compound and application thereof in-vivo tracing of nanoparticles 复旦大学 2022-10-04 CN claimed
CN-115141220-B Aza-BODIPY compound and application thereof in nanoparticle in-vivo tracking 复旦大学 2025-03-11 CN disclosed
CN-115141220-A Aza-BODIPY compound and application thereof in-vivo tracing of nanoparticles 复旦大学 2022-10-04 CN disclosed
CN-110283159-B 2, 4-disubstituted pyrrole or 2,3, 4-trisubstituted pyrrole prepared by one-pot method and preparation method thereof 河南大学 2020-09-29 CN disclosed
CN-110283159-A Tri- substituted azole of 2,3- disubstituted pyrroles or 2,3,4- and preparation method thereof of one kettle way preparation 河南大学 2019-09-27 CN disclosed
EP-1253151-B1 Pyrromethene metal complex and light emitting device composition and light emitting devices using the same TORAY INDUSTRIES (JP) 2005-01-12 EP disclosed
US-6805978-B2 COMPLEX CONTAINING DIKETOPYRROLO(3,4-C)PYRROLE COMPOUND TORAY INDUSTRIES, INC. (JP) 2004-10-19 US disclosed
US-20030082406-A1 Complex containing diketopyrrolo(3,4-c)pyrrole compound TORAY INDUSTRIES, INC. (JP) 2003-05-01 US disclosed
EP-1253151-A1 Pyrromethene metal complex and light emitting device composition and light emitting devices using the same TORAY INDUSTRIES, INC. (JP) 2002-10-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030082406-A1 Complex containing diketopyrrolo(3,4-c)pyrrole compound PPOX, CPNE4, TP53RK KDM4E 633/4885MAPT 1969/4885THRB 4482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.